AU2019233603B2 - Single domain antibodies binding to tetanus neurotoxin - Google Patents

Single domain antibodies binding to tetanus neurotoxin Download PDF

Info

Publication number
AU2019233603B2
AU2019233603B2 AU2019233603A AU2019233603A AU2019233603B2 AU 2019233603 B2 AU2019233603 B2 AU 2019233603B2 AU 2019233603 A AU2019233603 A AU 2019233603A AU 2019233603 A AU2019233603 A AU 2019233603A AU 2019233603 B2 AU2019233603 B2 AU 2019233603B2
Authority
AU
Australia
Prior art keywords
sda
binding
sdas
tent
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019233603A
Other languages
English (en)
Other versions
AU2019233603A1 (en
Inventor
Abraham Johannes De Smit
Michaël Marie HARMSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smivet BV
Original Assignee
Smivet BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smivet BV filed Critical Smivet BV
Publication of AU2019233603A1 publication Critical patent/AU2019233603A1/en
Application granted granted Critical
Publication of AU2019233603B2 publication Critical patent/AU2019233603B2/en
Priority to AU2025234234A priority Critical patent/AU2025234234A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019233603A 2018-03-13 2019-03-13 Single domain antibodies binding to tetanus neurotoxin Active AU2019233603B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025234234A AU2025234234A1 (en) 2018-03-13 2025-09-19 Single domain antibodies binding to tetanus neurotoxin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18161521 2018-03-13
EP18161521.2 2018-03-13
PCT/EP2019/056299 WO2019175250A1 (en) 2018-03-13 2019-03-13 Single domain antibodies binding to tetanus neurotoxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025234234A Division AU2025234234A1 (en) 2018-03-13 2025-09-19 Single domain antibodies binding to tetanus neurotoxin

Publications (2)

Publication Number Publication Date
AU2019233603A1 AU2019233603A1 (en) 2020-09-17
AU2019233603B2 true AU2019233603B2 (en) 2025-06-26

Family

ID=61691657

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019233603A Active AU2019233603B2 (en) 2018-03-13 2019-03-13 Single domain antibodies binding to tetanus neurotoxin
AU2025234234A Pending AU2025234234A1 (en) 2018-03-13 2025-09-19 Single domain antibodies binding to tetanus neurotoxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025234234A Pending AU2025234234A1 (en) 2018-03-13 2025-09-19 Single domain antibodies binding to tetanus neurotoxin

Country Status (10)

Country Link
US (2) US12054540B2 (https=)
EP (1) EP3765495A1 (https=)
JP (2) JP2021516682A (https=)
CN (2) CN117964751A (https=)
AU (2) AU2019233603B2 (https=)
BR (1) BR112020018563A2 (https=)
MA (1) MA51996A (https=)
MX (2) MX2020009507A (https=)
WO (1) WO2019175250A1 (https=)
ZA (1) ZA202403355B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4352521A4 (en) * 2021-06-07 2025-04-02 Martino, Michael, L. DIAGNOSIS AND TREATMENT BASED ON RAPID RECOGNITION
CN117624360A (zh) * 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034103A1 (en) * 1995-04-25 1996-10-31 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
GB9914861D0 (en) * 1999-06-25 1999-08-25 Imperial College Tetanus toxin polypeptides
AUPS022802A0 (en) * 2002-01-31 2002-02-21 Macfarlane Burnet Institute For Medical Research And Public Health Limited, The Anti-viral compounds
AU2004245429A1 (en) 2003-06-10 2004-12-16 Farallone Holding Bv Binding peptides: methods for their generation and use
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
AU2007219159B8 (en) * 2006-01-25 2012-06-28 Roger Kingdon Craig Generation of heavy-chain only antibodies in transgenic animals
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
BRPI1014253A2 (pt) * 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
BR112014011137A2 (pt) * 2011-11-09 2018-06-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento
US9670275B2 (en) * 2012-01-23 2017-06-06 Ablynx N.V. Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
AU2014301116B2 (en) * 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
CN107428840A (zh) * 2015-03-25 2017-12-01 弗劳恩霍夫应用研究促进协会 抗cd89细胞毒素的复合物
US9708412B2 (en) * 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034103A1 (en) * 1995-04-25 1996-10-31 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARBABI GHAHROUDI M. ET AL: "Selection and identification of single domain antibody fragments from camel heavy-chain antibodies", FEBS Letters, 1997, vol. 414, no. 3, pages 521–526, XP004261105, doi: 10.1016/S0014-5793(97)01062-4 *
ROSSOTTI M.A. ET AL: "Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain", MABS, 2015, vol. 7, no. 5, pages 820–828, XP055486850, doi: 10.1080/19420862.2015.1068491 *

Also Published As

Publication number Publication date
CN112135840A (zh) 2020-12-25
BR112020018563A2 (pt) 2020-12-29
JP2024023268A (ja) 2024-02-21
US12054540B2 (en) 2024-08-06
MX2025004782A (es) 2025-05-02
EP3765495A1 (en) 2021-01-20
WO2019175250A1 (en) 2019-09-19
AU2019233603A1 (en) 2020-09-17
US20220275066A1 (en) 2022-09-01
CN117964751A (zh) 2024-05-03
AU2025234234A1 (en) 2025-10-09
MX2020009507A (es) 2020-10-22
CN112135840B (zh) 2024-01-23
US20240376185A1 (en) 2024-11-14
MA51996A (fr) 2021-01-20
JP2021516682A (ja) 2021-07-08
ZA202403355B (en) 2024-12-18

Similar Documents

Publication Publication Date Title
JP7277370B2 (ja) 獣医用抗ｉｌ－３１抗体
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CN106414498B (zh) TNF α的结合成员
JP7241731B2 (ja) 血清アルブミン結合剤
US20240376185A1 (en) Tetanus prophylaxis
CN102584997A (zh) 针对肿瘤坏死因子-α的单结构域抗体及其用途
US9850315B2 (en) Antigen-binding protein directed against epitope in the CH1 domain of human IgG antibodies
KR20220155336A (ko) 수의학적 용도를 위한 항-il4 수용체 항체
JP2025517100A (ja) リラキシン又は類似体の融合タンパク質及びその医薬的使用
US20240228593A9 (en) SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
Harmsen et al. Serum immunoglobulin or albumin binding single-domain antibodies that enable tailored half-life extension of biologics in multiple animal species
US20260116958A1 (en) Antibodies to Botulinum Neurotoxins
US20250129141A1 (en) Antibody for tetanus toxin and use thereof
CA3198333A1 (en) Antibody compositions for treatment of corona virus infection
KR20230045095A (ko) Bcma와 결합하는 단일 가변 도메인 및 항원 결합 분자
CN1735629B (zh) 针对肿瘤坏死因子-α的单结构域抗体及其用途
US20180105584A1 (en) Antibody directed against immunoglobulin-binding proteins of s. aureus
US20230279084A1 (en) Antibodies to botulinum neurotoxins
US20250296993A1 (en) Anti-fel d 1 antibodies and antigen binding fragments thereof and uses thereof
RU2837141C2 (ru) Антитела к рецептору il4 для применения в ветеринарии
WO2023201192A2 (en) Antibodies to botulinum neurotoxins
KR20260042217A (ko) IgE 결합 단백질 및 이의 용도
HK40076787A (en) Anti-angptl3 antibody and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)